Stephens Investment Management Group’s Protagonist Therapeutics PTGX Stock Holding History

Stephens Investment Management Group’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.5M	Buy	+281,832	New	+$29.4M	0.37%	108

Other funds holding PTGX

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

LSERS

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Stephens Investment Management Group's PTGX Position: Q2 2026 in Review

Stephens Investment Management Group opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 281,832 shares worth $34.5M. The stake represents 0.37% of the portfolio and ranks #108 among its holdings.

65 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Stephens Investment Management Group held 281,832 shares of Protagonist Therapeutics worth $34.5M as of Q2 2026.
Protagonist Therapeutics was a new Stephens Investment Management Group position in Q2 2026.
Protagonist Therapeutics made up 0.37% of Stephens Investment Management Group's portfolio in Q2 2026, its #108 holding.
65 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Stephens Investment Management Group's 13F filing for Q2 2026, filed 29 Jul 2026.